

Sharlene Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8763470/publications.pdf>

Version: 2024-02-01

102
papers

4,829
citations

147801

31
h-index

95266

68
g-index

113
all docs

113
docs citations

113
times ranked

6849
citing authors

#	ARTICLE	IF	CITATIONS
1	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1797-1806.	1.6	913
2	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2231-2237.	1.6	611
3	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	7.4	412
4	PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3914-3920.	1.6	210
5	Role of cyclooxygenase-2 in colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 63-75.	5.9	163
6	Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. <i>Journal of Clinical Oncology</i> , 2003, 21, 2070-2076.	1.6	124
7	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 263-270.	8.1	121
8	<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4674-4681.	7.0	121
9	Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. <i>Cancer</i> , 2015, 121, 527-534.	4.1	118
10	Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 380-387.	4.1	93
11	Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. <i>BMC Cancer</i> , 2020, 20, 288.	2.6	86
12	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.	1.6	85
13	Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 969-977.	2.5	75
14	Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. <i>American Journal of Medicine</i> , 2003, 114, 56-58.	1.5	71
15	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?. <i>Oncologist</i> , 2006, 11, 624-629.	3.7	66
16	Obstacles to Residents' Conducting Research and Predictors of Publication. <i>Academic Medicine</i> , 2001, 76, 477.	1.6	65
17	Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 507-511.	1.3	61
18	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). <i>Investigational New Drugs</i> , 2008, 26, 265-272.	2.6	60

#	ARTICLE	IF	CITATIONS
19	Colorectal Cancer. Mayo Clinic Proceedings, 2007, 82, 114-129.	3.0	55
20	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. Canadian Journal of Neurological Sciences, 2003, 30, 269-271.	0.5	54
21	Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. Clinical Cancer Research, 2005, 11, 6466-6471.	7.0	54
22	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1436-1447.	1.6	53
23	Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. Seminars in Oncology, 2005, 32, 24-34.	2.2	49
24	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 779-786.	2.6	49
25	Adjuvant Chemotherapy for Stage III Colon Cancer: Does Timing Matter?. Diseases of the Colon and Rectum, 2011, 54, 1082-1089.	1.3	47
26	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.	2.3	41
27	Outcomes in Elderly Patients with Advanced Colorectal Cancer Treated with Capecitabine: A Population-Based Analysis. Clinical Colorectal Cancer, 2005, 5, 279-282.	2.3	38
28	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2016, 15, 179-185.	2.3	38
29	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa023.	2.9	36
30	Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. International Journal of Cancer, 2010, 126, 930-939.	5.1	35
31	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	3.7	33
32	Capecitabine-Induced Cerebellar Toxicity. Clinical Colorectal Cancer, 2006, 6, 70-71.	2.3	32
33	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Current Oncology, 2021, 28, 523-548.	2.2	31
34	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Annals of Surgical Oncology, 2011, 18, 3261-3270.	1.5	30
35	Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. Current Oncology, 2021, 28, 671-677.	2.2	27
36	Primary Tumor Resection in Patients Presenting With Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 52-55.	1.3	26

#	ARTICLE	IF	CITATIONS
37	Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis. <i>Clinical Colorectal Cancer</i> , 2011, 10, 97-101.	2.3	26
38	Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 321-328.	0.5	26
39	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , 2020, 26, 4599-4605.	7.0	26
40	Prognostic web-based models for stage II and III colon cancer. <i>Cancer</i> , 2011, 117, 4155-4165.	4.1	25
41	Trends in Chemotherapy Utilization for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 386-389.	2.3	24
42	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 156-163.	2.3	24
43	First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer. <i>Drugs</i> , 2004, 64, 27-44.	10.9	21
44	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. <i>Seminars in Oncology</i> , 2010, 37, 39-46.	2.2	21
45	Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: a 20-year retrospective review. <i>Medical Oncology</i> , 2011, 28, 1058-1061.	2.5	21
46	New targeted therapies in gastrointestinal cancers. <i>Current Treatment Options in Oncology</i> , 2003, 4, 393-403.	3.0	20
47	Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. <i>Cancer Treatment Reviews</i> , 2016, 50, 142-147.	7.7	19
48	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 552-554.	1.3	19
49	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. <i>Clinical Cancer Research</i> , 2014, 20, 4361-4369.	7.0	18
50	Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. <i>Cancer Treatment Reviews</i> , 2014, 40, 1171-1181.	7.7	18
51	Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 460-465.	1.3	18
52	Intraperitoneal Treatment for Peritoneal Mucinous Carcinomatosis of Appendiceal Origin After Operative Management. <i>Annals of Surgery</i> , 2009, 249, 588-595.	4.2	17
53	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 262-268.e1.	2.3	17
54	Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 203-210.	1.3	16

#	ARTICLE	IF	CITATIONS
55	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	5.1	16
56	Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience. <i>Cancer Investigation</i> , 2007, 25, 711-714.	1.3	14
57	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 25-30.	2.3	14
58	Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: A population-based longitudinal study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 863-868.	6.3	14
59	Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. <i>Journal of Oncology Practice</i> , 2009, 5, 153-158.	2.5	13
60	Effect of M1a and M1b Category in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 720-726.	3.7	13
61	Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 501-506.	0.9	12
62	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	1.3	12
63	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq1 1237843141gBT /O		
64	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 696-703.	2.5	11
65	Health information seeking behaviors among individuals with young-onset and average-onset colorectal cancer: an international cross-sectional survey. <i>Supportive Care in Cancer</i> , 2020, 28, 6011-6021.	2.2	11
66	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. <i>Current Oncology</i> , 2021, 28, 1558-1570.	2.2	11
67	Patterns of Diagnosis for Colorectal Cancer: Screening Detected vs. Symptomatic Presentation. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 573-577.	1.3	10
68	Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 259-64.	1.4	10
69	Massive Bleeding on a Bladder Protectant. <i>Archives of Internal Medicine</i> , 2002, 162, 1644.	3.8	8
70	Cetuximab, chemotherapy and KRAS status in mCRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 379-380.	27.6	8
71	Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 226-235.	3.8	8
72	Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 903-908.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 209-219.	3.8	7
74	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	1.9	6
75	New developments in therapy for colorectal cancer. Current Oncology Reports, 2003, 5, 183-191.	4.0	5
76	Real-world Impact of Availability of Adjuvant Therapy on Outcomes in Patients With Resected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 212-215.	1.3	4
77	Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 197.	0.2	4
78	Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient. CKJ: Clinical Kidney Journal, 2018, 11, 786-787.	2.9	4
79	A phase II trial of the effect of perindopril on handâ€™foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. Cancer Chemotherapy and Pharmacology, 2019, 83, 411-417.	2.3	4
80	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkab070.	2.9	4
81	Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action. Current Oncology, 2022, 29, 3149-3159.	2.2	4
82	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer, 2015, 14, 99-105.	2.3	3
83	A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. Archives of Clinical Neuropsychology, 2020, 35, 226-232.	0.5	2
84	Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers. Clinical Colorectal Cancer, 2022, 21, 107-113.	2.3	2
85	Hepatic Dysfunction During and After Lymphoma Chemotherapy in Patients With Hepatitis C. Journal of Clinical Gastroenterology, 2006, 40, 636-638.	2.2	1
86	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. Current Colorectal Cancer Reports, 2008, 4, 155-159.	0.5	1
87	Evolving end points for clinical trials in advanced colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 135-139.	0.5	1
88	Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Annals of Oncology, 2017, 28, iii153.	1.2	1
89	Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 788-791.	1.3	1
90	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 132-136.e3.	2.3	1

#	ARTICLE	IF	CITATIONS
91	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 468-468.	1.6	1
92	Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists. Current Oncology, 2021, 28, 4748-4755.	2.2	1
93	The Evolving Treatment Landscape of Hepatocellular Carcinoma: More Choices, More Responsibility. Current Oncology, 2020, 27, 136-137.	2.2	1
94	New developments in therapy for metastatic colorectal cancer. Current Colorectal Cancer Reports, 2005, 1, 13-17.	0.5	0
95	Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. Nature Clinical Practice Oncology, 2005, 2, 276-277.	4.3	0
96	The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study. Current Oncology, 2021, 28, 396-404.	2.2	0
97	Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. Journal of Gastrointestinal Oncology, 2021, 12, 446-454.	1.4	0
98	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. Journal of Clinical Oncology, 2012, 30, 443-443.	1.6	0
99	Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.. Journal of Clinical Oncology, 2017, 35, 710-710.	1.6	0
100	Real-world treatment attrition rates in advanced esophagogastric cancer. World Journal of Gastroenterology, 2020, 26, 6027-6036.	3.3	0
101	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. Current Oncology, 2020, 28, 2-3.	2.2	0
102	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. Current Oncology, 2021, 28, 2-3.	2.2	0